atorvastatin has been researched along with Hyperlipoproteinemias in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 9 (56.25) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, CM; Choi, D; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Kang, WC; Kim, BK; Kim, JS; Ko, YG; Lee, JB; Lee, JY; Lee, SJ; Lee, YJ; Yang, TH; Yoon, J | 1 |
| Adamova, IY; Afanasieva, OI; Akchurin, RS; Ezhov, MV; Il'ina, LN; Konovalov, GA; Matchin, YG; Pokrovsky, SN; Safarova, MS | 1 |
| Banach, M; Celecova, Z; Gaspar, L; Hirnerova, E; Huckova, N; Kucera, M; Oravec, S | 1 |
| Bogucki, J; Feldo, J; Feldo, M; Kęsik, J; Kocki, J; Lukasik, S; Terlecki, P; Wroński, J; Zubilewicz, T | 1 |
| Adamova, IY; Afanasieva, OI; Balakhonova, TV; Ezhov, MV; Konovalov, GA; Pogorelova, OA; Pokrovsky, SN; Safarova, MS; Tripoten, MI | 1 |
| Afanas'eva, MI; Afanas'eva, OI; Ezhov, MV; Liakishev, AA; Pokrovskiĭ, SN; Safarova, MS; Tripoten', MI; Trukhacheva, EP | 1 |
| Balogh, Z; Harangi, M; Illyés, L; Kovács, P; Paragh, G; Seres, I; Törocsik, D | 1 |
| Fujioka, D; Ichigi, Y; Kawabata, K; Kitta, Y; Kodama, Y; Kugiyama, K; Mende, A; Nakamura, T; Obata, JE; Saito, Y; Takano, H; Umetani, K | 1 |
| Frost, RJ; Otto, B; Otto, C; Parhofer, KG; Pfeiffer, AF; Spranger, J; Vogeser, M | 1 |
| Henry, K; Hermundson, J; Huebesch, J; Melroe, H; Simpson, J | 1 |
| de Man, FH; Mohrschladt, MF; Smelt, AH; Stoeken, DJ; Sturk, A; Westendorp, RG; Weverling-Rijnsburger, AW | 1 |
| Altman, R; Black, DM; Dujovne, CA; Harris, WS; Overhiser, RW | 1 |
| Bairaktari, ET; Elisaf, MS; Liberopoulos, EN; Milionis, HJ | 1 |
| Geiss, HC; Otto, C; Parhofer, KG; Schwandt, P | 1 |
| Azuma, A; Harada, S; Kunitomo, K; Kuwahara, N; Nakagawa, M; Sasaki, S; Takeda, K; Yamada, T | 1 |
| Brödl, UC; Empen, K; Otto, C; Parhofer, KG | 1 |
9 trial(s) available for atorvastatin and Hyperlipoproteinemias
| Article | Year |
|---|---|
Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Male; Middle Aged; Myocardial Infarction; Rosuvastatin Calcium; Stroke; Treatment Outcome | 2023 |
Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, LDL; Computed Tomography Angiography; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Female; Graft Occlusion, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Lipoprotein(a); Male; Middle Aged; Plasmapheresis; Prospective Studies; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Vascular Patency | 2017 |
Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels.
Topics: Adult; Atorvastatin; Biomarkers; Blood Component Removal; Carotid Artery Diseases; Carotid Artery, Common; Carotid Intima-Media Thickness; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Disease Progression; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Immunosorbent Techniques; Lipoprotein(a); Male; Middle Aged; Prospective Studies; Russia; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Up-Regulation | 2015 |
[Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein(a) levels].
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Atherosclerosis; Atorvastatin; Carotid Arteries; Coronary Artery Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipid Metabolism; Lipoprotein(a); Male; Middle Aged; Niacin; Plasminogen Activator Inhibitor 1; Pyrroles; Treatment Outcome; Tunica Intima | 2011 |
Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia.
Topics: Adult; Aged; Aryldialkylphosphatase; Atorvastatin; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipid Metabolism; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin | 2004 |
Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Bezafibrate; Biomarkers; Cholesterol; Coronary Artery Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors; Triglycerides; Vasodilation | 2005 |
Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia.
Topics: Adiponectin; Aged; Atorvastatin; Body Mass Index; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fenofibrate; Ghrelin; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Peptide Hormones; Pyrroles; Resistin | 2007 |
Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Bezafibrate; Cross-Over Studies; Cytokines; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Reference Values | 2000 |
The effects of three different LDL-apheresis methods on the plasma concentrations of E-selectin, VCAM-1, and ICAM-1.
Topics: Adsorption; Adult; Anticholesteremic Agents; Anticoagulants; Atorvastatin; Blood Component Removal; Cell Adhesion; Chelating Agents; Chemical Precipitation; Combined Modality Therapy; Coronary Disease; Dextran Sulfate; E-Selectin; Edetic Acid; Female; Hematocrit; Heparin; Heptanoic Acids; Humans; Hyperlipoproteinemias; Intercellular Adhesion Molecule-1; Lipids; Lipoproteins, LDL; Male; Pyrroles; Vascular Cell Adhesion Molecule-1 | 2002 |
7 other study(ies) available for atorvastatin and Hyperlipoproteinemias
| Article | Year |
|---|---|
Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Apolipoproteins B; Atherosclerosis; Atorvastatin; Biomarkers; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemias; Lipoproteins, LDL; Male; Middle Aged; Pilot Projects; Pyrroles; Time Factors; Treatment Outcome; Triglycerides | 2014 |
CIDE--A gene expression in patients with abdominal obesity and LDL hyperlipoproteinemia qualified for surgical revascularization in chronic limb ischemia.
Topics: Aged; Apoptosis Regulatory Proteins; Atorvastatin; Body Mass Index; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Humans; Hyperlipoproteinemias; Ischemia; Leg; Lipoproteins, LDL; Male; Metabolic Syndrome; Middle Aged; Obesity, Abdominal | 2013 |
Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities.
Topics: Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Gemfibrozil; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Protease Inhibitors; Pyrroles; Ritonavir; Saquinavir | 1998 |
Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Viscosity; Cholesterol, LDL; Cholesterol, VLDL; Fibrinogen; Heptanoic Acids; Humans; Hyperlipoproteinemias; Male; Middle Aged; Pilot Projects; Plasminogen Activator Inhibitor 1; Pyrroles; Single-Blind Method; Treatment Outcome; Triglycerides | 2000 |
Atorvastatin versus micronized fenofibrate in the treatment of patients with mixed hyperlipoproteinemia.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Fenofibrate; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Pyrroles | 2001 |
Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects.
Topics: Atorvastatin; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Lipoproteins, LDL; Male; Middle Aged; Pyrroles | 2001 |
Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Electrophoresis, Polyacrylamide Gel; Heptanoic Acids; Homocysteine; Humans; Hyperlipoproteinemias; Lipoprotein(a); Middle Aged; Pyrroles; Triglycerides | 2002 |